ASTRO guidelines for endometrial cancer endorsed by ASCO

This article originally appeared here.
Share this content:
ASCO Endorses ASTRO Guidelines for Endometrial Cancer
ASCO Endorses ASTRO Guidelines for Endometrial Cancer

(HealthDay News) -- The American Society of Clinical Oncology (ASCO) has endorsed postoperative radiation therapy guidelines for endometrial cancer, according to a report published online July 6 in the Journal of Clinical Oncology.

Larissa A. Meyer, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues reviewed the American Society for Radiation Oncology (ASTRO) guideline content and recommendations.

The authors note that the ASTRO recommendations are clear, thorough, and based on the most relevant evidence. For women without residual disease in the hysterectomy specimen, and for women with grade 1 or 2 cancer and <50 percent myometrial invasion, especially in the absence of other high-risk features, surveillance without adjuvant radiation therapy is reasonable. Vaginal brachytherapy is as effective as pelvic radiation therapy for prevention of vaginal recurrence, and is preferred for women with grade 1 or 2 cancer and ≥50 percent myometrial invasion or grade 3 cancer and <50 percent myometrial invasion. Pelvic radiation may be beneficial for preventing recurrence in women with grade 3 cancer and ≥50 percent myometrial invasion or cervical stroma invasion. Qualifying statements were added to the ASTRO recommendations to provide stronger statements in favor of chemotherapy for women with high-risk early-stage and advanced disease.

"ASCO endorses 'The Role of Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO Evidence-Based Guideline' by Klopp et al, published in 2014 in Practical Radiation Oncology, with qualifying statements," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs